Key points from webcast Q&A:
• Moderator asked whether OPT-302 could be co-formulated with Lucentis and/or Eylea (i.e. one injection). CEO said that OPT were very interested in co-formulating, noting that existing drugs are coming off patent in the next 12 months. Also noted that they don’t expect any roadblocks to co-formulating, i.e. there’s nothing in the chemistry of OPT-302 vs Lucentis/Eylea that suggests you would have issues
• Considering running a separate arm of the phase 3 trial to test ‘durability’, i.e frequency of injections. Compliance with anti-VEGF treatment programs isn’t great, so pushing out the frequency is a major focus for new drugs. CEO noted that this would be a nice to have, but the main game is the increased efficacy of OPT-302 combination treatment over existing drugs
• On partnering v financing independently, CEO noted that they’re well set up to move forward independently, but there are a lot of benefits to partnering. Didn’t commit either way
• On timing of finalizing capital requirements and potential partners, confirmed this would occur this year before they get too deep into phase 3
- Forums
- ASX - By Stock
- Ann: Opthea to Present at SVB Leerink Healthcare Conference
Key points from webcast Q&A:• Moderator asked whether OPT-302...
-
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
(20min delay)
|
|||||
Last
35.0¢ |
Change
-0.010(2.78%) |
Mkt cap ! $382.0M |
Open | High | Low | Value | Volume |
35.5¢ | 36.5¢ | 35.0¢ | $934.4K | 2.624M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 230715 | 35.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 17816 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 220529 | 0.350 |
11 | 831442 | 0.345 |
20 | 323131 | 0.340 |
7 | 368925 | 0.335 |
6 | 125505 | 0.330 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 43985 | 1 |
0.375 | 24450 | 2 |
0.380 | 145591 | 2 |
0.385 | 16756 | 2 |
0.390 | 7694 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online